A new research paper was published in Oncotarget, titled, "Everolimus downregulates STAT3/HIF-1α/VEGF pathway to inhibit angiogenesis and lymphangiogenesis in TP53 mutant head and neck squamous cell ...

Dysphagia in cancers of the lip, oral cavity, and pharynx patients: Impact on cachexia, hospitalization, and racial disparities on outcomes. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...

Preclinical study results suggest that targeting Hippo signaling may help address treatment resistance in acute myeloid leukemia.

TP53 mutations are crucial in cancer development and treatment response, influenced by genetic and environmental factors. In CLL and AML, TP53 serves as a significant prognostic marker, affecting ...

Despite the significance of immune checkpoint inhibitors (ICIs) in solid tumor treatment, identifying ICI-sensitive populations remains a challenge. Mutations in DNA damage response (DDR) pathway ...

Researchers at The University of Texas MD Anderson Cancer Center have discovered that an investigational epigenetic therapy remained effective in treatment-resistant acute myeloid leukemia (AML) ...

The strangely named hedgehog pathway that's crucial to bone growth has emerged as a key in the fight to treat the bone cancer osteosarcoma. Osteosarcoma is a type of bone cancer that primarily affects ...

Acute myeloid leukemia (AML) is a rare and aggressive hematologic malignancy. AML progresses rapidly and is indicated by an excess of immature white blood cells. It is caused by high mutational burden ...

BUFFALO, NY- February 9, 2023 – A new research paper was published in Oncotarget's Volume 14 on February 2, 2023, entitled, “Everolimus downregulates STAT3/HIF-1α/VEGF pathway to inhibit angiogenesis ...